Market capitalization | $265.28m |
Enterprise Value | $33.45m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.17 |
P/S ratio (TTM) P/S ratio | 1.35 |
P/B ratio (TTM) P/B ratio | 1.35 |
Revenue growth (TTM) Revenue growth | -33.22% |
Revenue (TTM) Revenue | $196.49m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Amylyx Pharmaceuticals forecast:
5 Analysts have issued a Amylyx Pharmaceuticals forecast:
Sep '24 |
+/-
%
|
||
Revenue | 196 196 |
33%
33%
|
|
Gross Profit | 61 61 |
78%
78%
|
|
EBITDA | -212 -212 |
3,037%
3,037%
|
EBIT (Operating Income) EBIT | -213 -213 |
2,658%
2,658%
|
Net Profit | -259 -259 |
14,202%
14,202%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Josh Klee |
Employees | 384 |
Founded | 2013 |
Website | www.amylyx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.